Aetna acquires Medicity Aetna today announced that it has completed its acquisition of Medicity Inc.
Aetna acquires Medicity Aetna today announced that it has completed its acquisition of Medicity Inc., a health info exchange technology company, headquartered in Salt Lake Town, Utah. A leading innovator in company solutions, Medicity offers a broad range of services and products that enable wellness systems, hospitals, physician methods and health details exchanges to securely access and exchange healthcare information, improving the performance and quality of patient care and reducing needless health care costs norethisterone pills . The transaction was announced on December 7, 2010.
Poster #3563 Entitled, ‘An extremely selective Erk 1/2 inhibitor with in-vivo anti tumor potency’, Irene Seipelt, Eckhard Guenther, Lars Blumenstein, Gilbert Mueller, Peter Schmidt, Babette Aicher, Michael Teifel and Matthias Gerlach . In in vivo pharmacokinetic studies, AEZS-131 showed a good PK profile. Anti-tumor activity was studied in in vivo mouse xenograft experiments utilizing the HCT-116 colon cancer model. AEZS-131 considerably inhibited tumor development and was well tolerated at daily dosages up to 120 mg/kg. Conclusion Concentrate on inhibition of downstream kinase Erk 1/2 activity as a therapeutic focus on may be attractive because the pharmacologic inhibition of Erk 1/2 reverses Ras and Raf activation in cells which also demonstrate level of resistance to common Raf inhibitors, such as for example PLX-4720/4032.